U.S. FDA Approves Pfizer Vaccine as Pandemic Reaches Critical Point
Investing.com
Published Dec 11, 2020 04:41PM ET
By Yasin Ebrahim
Investing.com – The Food and Drug Administration on Friday gave emergency authorization to the Pfizer-and-BioNTech Covid-19 vaccine as the pandemic reaches a critical point in the United States.
Pfizer (NYSE:PFE) rose 0.2% in aftermarket hours and BioNTech SE (NASDAQ:BNTX) was up 0.1%.
The emergency use is authorized for those aged 16 and older.
“The FDA’s authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world,” said FDA Commissioner Stephen M. Hahn, M.D., in a statement Friday night.
White House Chief of Staff Mark Meadows on Friday told Dr. Hahn to approve the vaccine by Friday, or hand in his resignation, the Washington Post reported earlier in the day, citing unnamed sources.
Health and Human Services Chief Alex Azar earlier Friday said he expected the vaccine to be available in the U.S. by Monday. The authorization paves the way for the vaccine to be rolled out quickly.
Earlier on Friday, Trump had called on Hahn to get the vaccine out, and accused the FDA commissioner of “playing games.”
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.